Serina Therapeutics (SER) Net Income (2018 - 2026)

Serina Therapeutics has disclosed Net Income across 9 years of filings, most recently posting -$7.0 million for Q2 2026.

• In Q2 2026, Net Income fell 25.35% year-over-year to -$7.0 million; the TTM figure through Jun 2026 stood at -$25.4 million (down 13.61% YoY), while the FY2025 annual figure was -$19.2 million, down 71.46% from the prior year.
• Net Income came in at -$7.0 million for Q2 2026 at Serina Therapeutics, down from -$6.4 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $65000.0 in Q4 2023 to a low of -$7.0 million in Q2 2026.
• Average Net Income over 5 years is -$3.7 million, with a median of -$2.8 million recorded in 2022.
• Year-over-year, Net Income soared 102.36% in 2023 and plunged 8663.08% in 2024.
• Over 5 years, Net Income stood at -$2.8 million in 2022, then soared by 102.36% to $65000.0 in 2023, then sank by 8663.08% to -$5.6 million in 2024, then retreated by 15.07% to -$6.4 million in 2025, then declined by 9.09% to -$7.0 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were -$7.0 million in Q2 2026, -$6.4 million in Q4 2025, and -$6.4 million in Q3 2025.